Boai NKY Medical Holdings Ltd. Class A

Boai NKY Medical Holdings Ltd. Class A

SSZSE:300109
9.66
CNY
-0.01
(-0.10%)
0.21EPS
59.87P/E
7.43BMarket Cap
Apr 26Next Earn
Boai NKY Medical Holdings Ltd. Class A
SZSE:300109
(Shenzhen Stock Exchange)

Recent

price

9.66

P/E

ratio

59.87

div

yld

1.83%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.79
0.72
0.77
0.8
0.93
0.93
1
1.23
1.78
1.88
1.71
2.1
2.49
2.81
2.79
2.01
2.1
Revenue per Share
0.11
0.09
0.07
0.08
0.11
0.18
0.2
0.23
0.23
0.25
0.08
0.36
0.49
0.88
0.61
0.33
0.22
Basic EPS, GAAP
-0.05
-0.38
-0.25
-0.05
- -
0.08
0.16
-0.21
-0.19
-0.13
0.29
-0.32
-0.02
0.2
-0.03
0.2
- -
Free Cash Flow per Basic Share
0.01
0.03
0.02
0.02
0.03
0.04
0.06
0.05
0.11
0.14
0.1
0.07
0.29
0.29
0.57
0.22
0.18
Dividend per Share
1.31
1.38
1.34
1.39
1.48
2.9
3.06
3.27
3.25
5.24
5.29
5.38
5.38
6.11
6.25
6.32
5.87
Book Value per Share
1.25
1.3
1.26
1.31
1.39
1.66
1.78
1.99
1.95
1.4
1.44
4.59
4.54
5.26
5.5
5.58
5.12
Tangible Book Value per Share
208
266
277
263
272
311
400
398
393
491
573
582
596
563
575
585
576
Basic Weighted Avg Shares
163
191
213
209
253
291
401
489
698
924
979
1,220
1,486
1,583
1,606
1,178
1,207
Sales/Revenue/Turnover
16.02
12.4
9.26
11.52
14.26
22.63
24.21
23.77
21.8
25.08
16.26
13.08
29.32
37.2
29.24
25.24
21.56
Operating Margin (%)
6
7
7
10
19
24
32
36
39
43
52
72
62
74
102
110
- -
Depreciation Expense
23
25
20
20
30
57
80
93
90
123
45
207
291
493
350
190
124
Net Income, GAAP
13.44
13.75
12.28
13.62
14.19
14.99
15.15
14.69
13.99
20.8
51.3
32.38
27.55
17.01
14.02
21.43
20.3
Effective Tax Rate (%)
14.1
13.07
9.43
9.63
11.89
19.61
19.98
19
12.82
13.28
4.56
16.97
19.62
31.14
21.77
16.14
10.26
Profit Margin (%)
264
175
104
85
83
326
353
9
-329
154
75
1,602
931
760
805
1,010
600
Working Capital
- -
1
1
- -
1
1
10
- -
18
127
54
54
50
33
22
155
177
LT Debt
333
351
364
377
400
1,163
1,227
1,302
1,276
3,053
3,076
3,314
3,117
3,520
3,608
3,655
3,355
Total Equity
9.85
6.57
5.03
5.17
7.49
7.09
6.56
5.92
4.86
4.2
0.81
5.34
8.56
14.66
9.54
4.83
- -
Return on Invested Capital (%)
11.69
7.32
5.61
5.4
7.59
7.29
7.08
6.22
6.16
5.33
2.07
6.71
9.19
14.83
9.44
4.98
- -
Return on Capital (%)
11.65
7.29
5.62
5.44
7.75
7.29
6.7
7.34
6.95
5.68
1.46
6.47
9.02
14.76
9.74
5.19
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
174
397
345
LT Borrowings
154
153
176
LT Finance Leases
1
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
580
577
577
Market Capitalization
8,280
9,259
7,430

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,475
1,391
1,390
Cash, Cash Equivalents & STI
672
547
527
Accounts Receivable, Net
309
337
380
Inventories
295
280
270
Total Current Liabilities
460
767
791
Payables & Accruals
- -
- -
- -
ST Debt
174
397
345
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.81%
3.7%
1.32%
Free Cash Flow
-246.49%
-405.17%
-730.87%
Net Income, GAAP
42.6%
79.94%
-45.64%
Sales/Revenue/Turnover
16.88%
5.57%
-26.66%
Total Cash Common Dividend
55.2%
63.94%
-60.67%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
395
340
376
495
1,606
2025
325
319
- -
227
1,178
2026
342
336
303
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.16
0.17
0.07
0.61
2025
0.14
0.1
- -
-0.02
0.33
2026
0.11
0.06
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.56
- -
- -
0.57
2025
- -
- -
- -
0.01
0.22
2026
- -
0.17
- -
- -
- -
Business
Boai NKY Medical Holdings Ltd engages principally in the research, development, production, and distribution of fine chemical and precision medicine products. Founded in 2003 and headquartered in Jiaozuo, China, the company operates primarily in China with international distribution networks. Its main product lines include polyvinyl pyrrolidone (PVP) series products such as KoVidone and PolyKoVidone used as pharmaceutical excipients; vinyl methyl ether/maleic anhydride copolymer (PVM/MA) branded as OraRez bioadhesive polymers; pharmaceutical solvents and intermediates; and specialized polymers for diverse industries including pharmaceuticals, oral care, cosmetics, food and beverage, and industrial applications. Additionally, the company provides precision medicine services focusing on in vitro diagnostic products, early tumor screening, molecular diagnostics, and individualized precision medicine leveraging gene sequencing technology. Recent major developments include a strategic emphasis on innovation and sustainability, with significant investments in R&D facilities located in Boai, Tianjin, and Shanghai to advance polymer chemistry, production automation, and product consistency. The company has reinforced its competitive moat in pharmaceutical excipients through improved new product capacities and environmental responsibility in manufacturing processes. Boai NKY also maintains strict cGMP and EXCiPACT™ GMP-certified quality systems to support its global pharmaceutical partners. Financially, the company reported some decline in third-quarter 2024 revenue and profit margins compared to the prior year yet continues to expand its product portfolio and global market reach. Its robust product lines in excipients and intermediates remain core to its industrial and pharmaceutical operations. Boai NKY Medical Holdings presents a comprehensive product offering in pharmaceutical and industrial polymers, combining legacy expertise in PVP chemistry with modern precision medicine technologies and sustained R&D commitments. Its operations center around chemical manufacturing and medical diagnostics primarily serving healthcare, pharmaceutical, and multiple industrial sectors with products supporting drug formulation, stability, and bioavailability enhancement. This positions Boai NKY as a key player in the pharmaceutical excipients and fine chemicals market, leveraging its technical expertise, diversified product range, and expanding medical services to drive growth and innovation. All information is current as of late 2025 and drawn from company disclosures, financial reports, and industry sources.